| Literature DB >> 31223622 |
Abstract
OBJECTIVES: The purpose of this study was to explore the association of miRNA-146 and miRNA-499 polymorphisms with inflammatory arthritis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31223622 PMCID: PMC6541972 DOI: 10.1155/2019/7305750
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1A flowchart of the included and excluded studies.
The main features of included studies.
| Author | Year | Disease | Country | Region | Genotyping methods | Number of Cases | Number of controls | Characteristics of controls | Polymorphisms | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Chatzikyriakidou A | 2010 | RA | Greece | Europe | PCR–RFLP | 136 | 147 | Healthy | rs2910164(miRNA-146) | 6 |
|
| ||||||||||
| Yang XK | 2016 | RA | China | Asia | TaqMan | 386 | 576 | Healthy | rs3746444(miRNA-499) | 7 |
|
| ||||||||||
| Singh S | 2014 | JIA-ERA | India | Asia | PCR–RFLP | 150 | 216 | Healthy | rs2910164(miRNA-146) | 7 |
|
| ||||||||||
| El-Shal AS | 2013 | RA | Egypt | Middle East | PCR–RFLP | 217 | 245 | Healthy | rs2910164(miRNA-146), | 6 |
|
| ||||||||||
| Shaker OG | 2018 | RA | Egypt | Middle East | TaqMan | 104 | 112 | Healthy | rs2910164(miRNA-146), | 7 |
|
| ||||||||||
| Hashemi M | 2012 | RA | Iran | Middle East | T-ARMS-PCR | 104 | 110 | Healthy | rs2910164(miRNA-146), | 6 |
|
| ||||||||||
| Yang B | 2010 | RA | China | Asia | PCR–RFLP | 208 | 240 | Healthy | rs2910164(miRNA-146), | 7 |
|
| ||||||||||
| Aleman-Avila I | 2017 | RA | Mexico | North America | TaqMan | 412 | 486 | Healthy | rs2910164(miRNA-146), | 7 |
|
| ||||||||||
| Zhou X | 2015 | RA | China | Asia | NA | 598 | 821 | NA | rs2910164(miRNA-146) | 5 |
|
| ||||||||||
| Hassine HB | 2017 | RA | Tunisia | Middle East | PCR–RFLP | 165 | 150 | Healthy | rs2910164(miRNA-146) | 6 |
|
| ||||||||||
| Maharaj AB(1) | 2018 | PsA | South Africa | Africa | PCR–RFLP | 84 | 62 | Healthy | rs2910164(miRNA-146) | 6 |
|
| ||||||||||
| Maharaj AB(2) | 2018 | PsA | South Africa | Africa | PCR–RFLP | 32 | 38 | Healthy | rs2910164(miRNA-146) | 6 |
|
| ||||||||||
| Jimenez-Morales S | 2012 | JRA | Mexico | North America | TaqMan | 210 | 531 | Healthy | rs2910164(miRNA-146) | 7 |
|
| ||||||||||
| Ciccacci C | 2016 | RA | Italy | Europe | TaqMan | 192 | 298 | Healthy | rs2910164(miRNA-146) | 7 |
|
| ||||||||||
| Ayeldeen G | 2018 | RA | Egypt | Middle East | real-time PCR | 52 | 56 | Healthy | rs2910164(miRNA-146), | 6 |
|
| ||||||||||
| Toraih EA | 2016 | RA | Egypt | Middle East | TaqMan | 95 | 200 | Healthy | rs3746444(miRNA-499), | 6 |
|
| ||||||||||
| Fattah SA | 2018 | RA | Egypt | Middle East | PCR–RFLP | 100 | 100 | Healthy | rs3746444(miRNA-499) | 6 |
|
| ||||||||||
| Bogunia-Kubik K | 2016 | RA | Poland | Europe | PCR–RFLP | 111 | 130 | Healthy | rs2910164(miRNA-146) | 6 |
|
| ||||||||||
| Chatzikyriakidou A | 2010 | PsA | Greece | Europe | PCR–RFLP | 29 | 66 | NA | rs2910164(miRNA-146) | 6 |
HWE: Hardy–Weinberg equilibrium; NOS: Newcastle-Ottawa Quality Assessment Scale.
Figure 2The forest plot about association between miRNA-146 rs2910164 and inflammatory arthritis under allelic model (G vs C).
Figure 3The forest plot about association between miRNA-499 rs3746444 and inflammatory arthritis under allelic model (C vs T).
The results of meta-analysis, heterogeneity test, and publication bias.
| polymorphism | Number of studies | Comparable genotype | No. of Cases/Controls | Test of association | Test of heterogeneity | Test of publication bias | Model | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Begg's test | Egger's test | ||||||||||||
| OR (95%CI) |
|
|
| Z |
| t |
| ||||||
| rs2910164 | |||||||||||||
| Overall | 16 | G vs C | 2802/3708 | 1.061(0.933-1.207) | 0.365 | 58.80% | 0.002 | 0.14 | 0.893 | 0.60 | 0.559 | R | |
| Region | |||||||||||||
| Europe | 4 | G vs C | 468/641 | 1.017(0..836-1.236) | 0.868 | 0.00% | 0.753 | 1.02 | 0.308 | -2.93 | 0.100 | F | |
| Asia | 3 | G vs C | 956/1277 | 0.991(0.877-1.120) | 0.890 | 0.00% | 0.412 | 1.04 | 0.296 | -1.89 | 0.309 | F | |
| Middle East | 5 | G vs C | 642/673 | 1.449(1.229-1.709) | 0.001 | 47.30% | 0.108 | 0.24 | 0.806 | 0.53 | 0.630 | F | |
| Africa | 2 | G vs C | 116/100 | 0.615(0.405-0.935) | 0.023 | 0.50% | 0.316 | 0.00 | 1.000 | NA | NA | F | |
| North America | 2 | G vs C | 620/1017 | 0.955(0.820-1.111) | 0.551 | 36.40% | 0.210 | 0.00 | 1.000 | NA | NA | F | |
| HWE | |||||||||||||
| Y | 13 | G vs C | 2524/3359 | 1.053(0.916-1.211) | 0.469 | 61.90% | 0.002 | 0.18 | 0.855 | 0.99 | 0.344 | R | |
| Overall | 16 | GC+CC | 2802/3708 | 0.919(0.762-1.110) | 0.381 | 57.20% | 0.002 | -0.05 | 1.000 | 0.05 | 0.963 | R | |
| Region | |||||||||||||
| Europe | 4 | GC+CC | 468/641 | 1.000(0.784-1.276) | 0.998 | 0.00% | 0.606 | 1.70 | 0.089 | 13.66 | 0.005 | F | |
| Asia | 3 | GC+CC | 956/1277 | 0.980(0.795-1.209) | 0.851 | 0.00% | 0.869 | 0.00 | 1.000 | 0.16 | 0.896 | F | |
| Middle East | 5 | GC+CC vs GG | 642/673 | 0.530(0.320-0.877) | 0.014 | 64.30% | 0.024 | 0.73 | 0.462 | -0.99 | 0.394 | R | |
| Africa | 2 | GC+CC vs GG | 116/100 | 1.915(1.107-3.314) | 0.020 | 49.40% | 0.160 | 0.00 | 1.000 | NA | NA | F | |
| North America | 2 | GC+CC vs GG | 620/1017 | 1.009(0.735-1.385) | 0.956 | 57.20% | 0.127 | 0.00 | 1.000 | NA | NA | R | |
| HWE | |||||||||||||
| Y | 13 | GC+CC vs GG | 2524/3359 | 0.942(0.780-1.137) | 0.532 | 55.80% | 0.007 | 0.06 | 0.951 | 0.02 | 0.982 | R | |
| Overall | 16 | CC vs GG+GC | 2802/3708 | 0.935(0.821-1.065) | 0.310 | 34.60% | 0.086 | 1.22 | 0.224 | 0.98 | 0.343 | F | |
| Region | |||||||||||||
| Europe | 4 | CC vs GG+GC | 468/641 | 0.914(0.581-1.439) | 0.699 | 0.00% | 0.839 | -0.34 | 1.000 | 0.23 | 0.837 | F | |
| Asia | 3 | CC vs GG+GC | 956/1277 | 1.149(0.803-1.645) | 0.447 | 59.10% | 0.087 | 1.04 | 0.296 | 2.69 | 0.227 | R | |
| Middle East | 5 | CC vs GG+GC | 642/673 | 0.631(0.483-0.823) | 0.001 | 0.00% | 0.431 | 0.24 | 0.806 | -0.60 | 0.590 | F | |
| Africa | 2 | CC vs GG+GC | 116/100 | 2.211(0.674-7.256) | 0.191 | 0.00% | 0.581 | 0.00 | 1.000 | NA | NA | F | |
| North America | 2 | CC vs GG+GC | 620/1017 | 1.151(0.837-1.582) | 0.387 | 0.00% | 0.739 | 0.00 | 1.000 | NA | NA | F | |
| HWE | |||||||||||||
| Y | 13 | CC vs GG+GC | 2524/3359 | 0.959(0.834-1.103) | 0.556 | 40.20% | 0.066 | 0.55 | 0.583 | 0.37 | 0.722 | F | |
| rs3746444 | |||||||||||||
| Overall | 9 | C vs T | 1678/2125 | 1.422(1.159-1.745) | 0.001 | 63.30% | 0.005 | 1.15 | 0.251 | 1.30 | 0.234 | R | |
| Region | |||||||||||||
| Asia | 2 | C vs T | 594/816 | 1.128(0.904-1.406) | 0.286 | 0.00% | 0.573 | 0.00 | 1.000 | NA | NA | F | |
| Middle East | 6 | C vs T | 672/823 | 1.614(1.219-2.137) | 0.001 | 66.80% | 0.010 | 0.75 | 0.452 | 0.77 | 0.485 | R | |
| North America | 1 | C vs T | 412/486 | 1.215(0.845-1.748) | 0.294 | NA | NA | NA | NA | NA | NA | F | |
| HWE | |||||||||||||
| Y | 7 | C vs T | 1479/1815 | 1.390(1.214-1.591) | 0.001 | 31.00% | 0.191 | 0.30 | 0.764 | 0.99 | 0.368 | F | |
| Overall | 9 | TC+CC vs TT | 1678/2125 | 1.409(1.072-1.852) | 0.014 | 67.50% | 0.002 | 0.10 | 0.917 | 1.03 | 0.335 | R | |
| Region | |||||||||||||
| Asia | 2 | TC+CC vs TT | 594/816 | 1.138(0.891-1.454) | 0.301 | 0.00% | 0.374 | 0.00 | 1.000 | NA | NA | F | |
| Middle East | 6 | TC+CC vs TT | 672/823 | 1.634(1.062-2.513) | 0.026 | 73.40% | 0.002 | 0.75 | 0.452 | 0.10 | 0.924 | R | |
| North America | 1 | TC+CC vs TT | 412/486 | 1.188(0.809-1.742) | 0.379 | NA | NA | NA | NA | NA | NA | F | |
| HWE | |||||||||||||
| Y | 7 | TC+CC vs TT | 1479/1815 | 1.399(1.190-1.645) | 0.001 | 38.20% | 0.138 | 0.00 | 1.000 | 1.11 | 0.319 | F | |
| Overall | 9 | CC vs TT+TC | 1678/2125 | 1.872(1.420-2.467) | 0.001 | 0.00% | 0.588 | 0.10 | 0.917 | 0.42 | 0.686 | F | |
| Region | |||||||||||||
| Asia | 2 | CC vs TT+TC | 594/816 | 1.224(0.551-2.717) | 0.619 | 0.00% | 0.495 | 0.00 | 1.000 | NA | NA | F | |
| Middle East | 6 | CC vs TT+TC | 672/823 | 1.960(1.455-2.641) | 0.001 | 0.00% | 0.462 | 0.38 | 0.707 | 0.66 | 0.545 | F | |
| North America | 1 | CC vs TT+TC | 412/486 | 3.557(0.369-34.331) | 0.273 | NA | NA | NA | NA | NA | NA | F | |
| HWE | |||||||||||||
| Y | 7 | CC vs TT+TC | 1479/1815 | 1.910(1.334-2.736) | 0.001 | 0.00% | 0.696 | 0.00 | 1.000 | -0.21 | 0.840 | F | |
R: random-effects model; F: fixed-effects model; Y: yes (studies that suitable for HWE); PH: the value of P in the heterogeneity test.
Figure 4The plot of sensitivity analysis about association between miRNA-499 rs3746444 and inflammatory arthritis.